| 摘要: |
| ［摘要］ 近年来，胃肠间质瘤(GIST)在分子标记物、基因检测、靶向治疗药物药效评估等方面的研究有诸多进展。DOG1、PKC-θ、ETV1等新的标记物的发现有助于提高GIST的检出率，同时为寻找新的靶向治疗的靶点提供了方向。目前伊马替尼作为靶向治疗一线药物对于改善GIST患者的预后有重要意义，其耐药机制及新的靶向药物的研制仍需要进一步探索研究。该文对GIST分子病理诊断及靶向治疗的研究进展进行综述。 |
| 关键词: 胃肠间质瘤 诊断 靶向治疗 进展 |
| DOI：10.3969/j.issn.1674-3806.2015.04.26 |
| 分类号:R 735 |
| 基金项目:广西卫计委科研课题（编号:Z2014205） |
|
| Recent advances in molecular pathological diagnosis and targeted therapy of gastrointestinal stromal tumors |
|
NONG Tao, YIN Wu, ZHONG Xiao-gang
|
|
Department of Gastrointestinal and Peripheral Vascular Surgery, the People′s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China
|
| Abstract: |
| ［Abstract］ In recent years, there are a lot of progress in these areas of gastrointestinal stromal tumor(GIST) include molecular markers, gene detection, targeted therapy drugs efficacy assessment. Discovery of DOG1, PKC-θ, ETV1 and other new markers helps to improve the detection rate of GIST, and provide new direction for discovering special therapeutic targets. Currently imatinib as first-line drugs for targeted therapy has great significance for improving the prognosis of patients with GIST, mechanisms of drug resistance and the development of new targeted drugs still need further exploration and research. In this paper, the recent advances in molecular pathological diagnosis and targeted therapy of GIST were reviewed. |
| Key words: Gastrointestinal stromal tumors(GIST) Diagnosis Targeted therapy Recent advances |
